ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446

Its studies are led by Johnson & Johnson.

Furthest: phase 1, since Aug 5, 20251 company-led study, 1 open or runningNext primary completion: Nov 18, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 1since Aug 5, 2025Aug 5, 2025Nov 18, 2027phase 1 · NCT07107230
  • Named in Johnson & Johnson’s own pipeline as JNJ-7446, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 5, 2025First study: phase 1 study in Advanced Stage Solid TumorsFirst studyNCT07107230 · 400 planned · United States, South Korea, Spain

Ahead

  1. Nov 18, 2027Primary completion: phase 1 study in Advanced Stage Solid TumorsNCT07107230

TargetBeta

“An antibody-drug conjugate (ADC) composed of amivantamab, a human bispecific immunoglobulin G1 (IgG1) antibody targeting the two tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), linked to CPT-113, a dual-maleimide cleava…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of amivantamab, a human bispecific immunoglobulin G1 (IgG1) antibody targeting the two tumor-associated antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR; c-Met), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
amivantamabruleJohnson & Johnsonphase 316
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
pamvatamigruleBetta Pharmaceuticalsphase 25
TQB2922Sino Biopharmaceuticalphase 25
TQB6411Sino Biopharmaceuticalphase 23
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 21
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruletavotek-biotherapeuticsphase 12
HS-20122Hansoh Pharmaceutical Groupphase 12
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 11
HLX48Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07107230Advanced Stage Solid Tumors · United States, South Korea, Spain1RecruitingNov 18, 2027400

How it is read

Names in the registry

  • “JNJ-95437446”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.